

A Conservative Assessment of the Major Genetic Causes of Idiopathic Chronic Pancreatitis: Data from a Comprehensive Analysis of *PRSS1*, *SPINK1*, *CTRC* and *CFTR* Genes in 253 Young French Patients

Emmanuelle Masson^{1,2}, Jian-Min Chen^{1,3*}, Marie-Pierre Audrézet^{1,2}, David N. Cooper⁴, Claude Férec^{1,2,3,5*}

1 Institut National de la Santé et de la Recherche Médicale, U1078, Brest, France, 2 Laboratoire de Génétique Moléculaire et d'Histocompatibilité, Centre Hospitalier Régional Universitaire Brest, Hôpital Morvan, Brest, France, 3 Etablissement Français du sang – Bretagne, Brest, France, 4 Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom, 5 Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France

Abstract

Idiopathic chronic pancreatitis (ICP) has traditionally been defined as chronic pancreatitis in the absence of any obvious precipitating factors (e.g. alcohol abuse) and family history of the disease. Studies over the past 15 years have revealed that ICP has a highly complex genetic architecture involving multiple gene loci. Here, we have attempted to provide a conservative assessment of the major genetic causes of ICP in a sample of 253 young French ICP patients. For the first time, conventional types of mutation (comprising coding sequence variants and variants at intron/exon boundaries) and gross genomic rearrangements were screened for in all four major pancreatitis genes, *PRSS1*, *SPINK1*, *CTRC* and *CFTR*. For the purposes of the study, synonymous, intronic and 5'- or 3'-untranslated region variants were excluded from the analysis except where there was persuasive evidence of functional consequences. The remaining sequence variants/genotypes were classified into causative, contributory or neutral categories by consideration of (i) their allele frequencies in patient and normal control populations, (ii) their presumed or experimentally confirmed functional effects, (iii) the relative importance of their associated genes in the pathogenesis of chronic pancreatitis and (iv) gene-gene interactions wherever applicable. Adoption of this strategy allowed us to assess the pathogenic relevance of specific variants/genotypes to their respective carriers to an unprecedented degree. The genetic cause of ICP could be assigned in 23.7% of individuals in the study group. A strong genetic susceptibility factor was also present in an additional 24.5% of cases. Taken together, up to 48.2% of the studied ICP patients were found to display evidence of a genetic basis for their pancreatitis. Whereas these particular proportions may not be extrapolable to all ICP patients, the approach employed should serve as a useful framework for acquiring a better understanding of the role of genetic factors in causing this oligogenic disease.

Citation: Masson E, Chen J-M, Audrézet M-P, Cooper DN, Férec C (2013) A Conservative Assessment of the Major Genetic Causes of Idiopathic Chronic Pancreatitis: Data from a Comprehensive Analysis of *PRSS1*, *SPINK1*, *CTRC* and *CFTR* Genes in 253 Young French Patients. PLoS ONE 8(8): e73522. doi:10.1371/journal.pone.0073522

Editor: Francisco X. Real, Centro Nacional de Investigaciones Oncológicas (CNIO), Spain

Received: May 20, 2013; **Accepted:** July 30, 2013; **Published:** August 8, 2013

Copyright: © 2013 Masson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Association des Pancréatites Chroniques Héritaires (APCH), France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: Jian-Min.Chen@univ-brest.fr (J-MC); claude.ferec@univ-brest.fr (CF)

Introduction

Chronic pancreatitis, a persistent inflammation of the pancreas that results in irreversible morphological changes and impairment of both exocrine and endocrine functions, is a potentially life-threatening disease. In Western countries, alcohol abuse is the leading cause of chronic pancreatitis, accounting for approximately 70% of all cases. Other aetiological factors, including hyperparathyroidism,

hypertriglyceridemia, duct obstruction, trauma, pancreas divisum, autoimmune pancreatitis and hereditary pancreatitis, are responsible for causing the disease in approximately 10% of patients. The remaining ~20% of cases, in which none of the abovementioned aetiological factors can be identified, have been collectively termed idiopathic chronic pancreatitis (ICP) [1].

Over the past 15 years, the importance of genetic factors in the aetiology of ICP has been increasingly recognized. This

began with the report of an association between *CFTR* (cystic fibrosis transmembrane conductance regulator; MIM #602421) mutations and ICP in 1998 [2,3]. In the human exocrine pancreas, *CFTR* is predominantly expressed at the apical plasma membrane of the ductal and centroacinar cells that line the small pancreatic ducts, and controls cAMP-stimulated HCO_3^- secretion into the duct lumen [4–6]. The major function of *CFTR* in the pancreas is to dilute and alkalize the protein-rich acinar secretions, thereby preventing the formation of protein plugs that predispose to pancreatic injury [7,8]. Whereas the presence of two highly deleterious ('severe') *CFTR* alleles (as in p.F508del homozygotes) is necessary to give rise to classic cystic fibrosis, heterozygosity for such an allele is sufficient to confer an increased risk of ICP, whilst compound heterozygosity, involving a severe *CFTR* allele plus a less deleterious ('mild') allele (e.g. p. F508del/p.R117H), confers a further increase in risk [7,8]. Since cystic fibrosis carriers (i.e. individuals harbouring a heterozygous severe *CFTR* allele) correspond to 3% of the general population in many European countries, *CFTR* mutations represent a major risk factor for ICP [7,8].

Gain-of-function *PRSS1* (encoding cationic trypsinogen; MIM #276000) missense mutations were first reported in individuals with ICP in 1999 [9,10], three years after the identification of *PRSS1* as a causative gene for hereditary pancreatitis [11]. In addition to gain-of-function missense mutations, gain-of-function *PRSS1* gene duplication and triplication copy number mutations have also been found in ICP patients [12]. Finally, and most importantly, the involvement of *PRSS1* contributed directly to the identification of two further chronic pancreatitis susceptibility genes, *SPINK1* (encoding pancreatic secretory trypsin inhibitor; MIM #167790) [13] and *CTRC* (encoding chymotrypsin C, a trypsin-degrading enzyme [14]; MIM #601405) [15,16]. Given that in the pancreas, *PRSS1*, *SPINK1* and *CTRC* are expressed exclusively in the acinar cells, these genetic findings suggested an important role for prematurely activated trypsinogen within the pancreatic acini in initiating chronic pancreatitis [8,17,18].

The abovementioned four genes represent the most extensively studied chronic pancreatitis-causing (or predisposing) genes identified to date. However, only very recently were they all analysed together in a single study of ICP [19]. Such an analysis is essential for an assessment of each gene's relative contribution to the aetiology of the disease and to reveal the potential interactions between the different genes/gene products. However, Rosendahl et al. [19] included both ICP and hereditary pancreatitis patients in their study and only screened for micro-lesions (not gross rearrangements) in the four genes. In addition, they focused on the overall contribution of *CFTR* variants to the aetiology of chronic pancreatitis at the population level. In the current study, we have performed a comprehensive mutation screening analysis of all four known pancreatitis genes in a relatively large and clinically homogenous sample of French ICP patients. In contrast to the Rosendahl study [19], we opted to assess the pathogenic relevance (i.e. causative or contributory) of the detected variants/genotypes to their respective carriers. This

strategy allowed us to assign genetic causality in a significant fraction of our ICP patients.

Materials and Methods

Ethics statement

This study was approved by the Ethical Review Committee of the Université de Bretagne Occidentale. All participating patients provided informed consent for genetic analysis.

Patients

In accordance with our previous studies [12,16], ICP was defined as chronic pancreatitis in the absence of any obvious precipitating factors (e.g. alcohol abuse, infection or trauma) and in the absence of a positive family history; whilst "young" ICP patients were defined as those patients in whom the age of disease onset was known to be ≤ 20 years or in whom the diagnosis of chronic pancreatitis was made before the age of 20. A total of 253 young French ICP patients were included in this study; they represent those young ICP patients who were recruited from both public and private clinics/hospitals in mainland France between February 1998 and July 2007 and whose DNA samples were available for the mutational analysis of the *CFTR*, *PRSS1*, *SPINK1* and *CTRC* genes. Most of the patients have been previously reported [12,16].

Screening for point mutations and micro-insertions/micro-deletions in the four major pancreatitis genes

All exons and exon/intron junctions of the *PRSS1* and *SPINK1* genes were analysed using previously described denaturing high-performance liquid chromatography methods [20,21].

Exons and exon/intron junctions of the *CFTR* gene were screened by either denaturing high-performance liquid chromatography [22] and/or high-resolution DNA melting analysis [23]. Additionally, the *CFTR* intron 8 poly(T) variants were analysed according to the method of Friedman and colleagues [24] whilst the poly(TG) repeat number in individuals carrying the *CFTR* intron 8 5T allele was assessed using the fluorescent multiplex PCR method of Mantovani et al. [25].

All exons of the *CTRC* gene and their immediate flanking sequences were analysed by direct sequencing as previously described [16].

Screening for gross genomic rearrangements or copy number variation in the four major pancreatitis genes

Gross genomic rearrangements or copy number mutations in the four major pancreatitis genes were sought by means of quantitative fluorescent multiplex-PCR as described elsewhere [16,26–28].

Principles for variant/genotype classification

To provide a conservative assessment of the extent of the genetic basis of ICP in the studied subjects and for the sake of simplicity, certain variants of unknown functional significance were first excluded from the analysis (Figure 1A). The

remaining sequence variants/genotypes were then sub-classified into causative, contributory or neutral categories (Figure 1A) through consideration of four specific factors (Figure 1B).

Results and Discussion

Characteristics of the patient cohort

The patient cohort comprised 253 subjects and was characterized by two features. First, it included only subjects with clinically well-defined ICP as ascertained by experienced clinicians. Second, it included only young patients (age at diagnosis or age of onset ≤ 20 years). A major advantage of employing this homogeneous patient sample for genetic analysis is that interference from potential confounding factors should be significantly reduced.

Mutation data analysis and classification

This study is the first to have analysed both intragenic mutations and gross genomic rearrangements in all four genes in a group of ICP patients. Apart from the *PRSS1* gene duplication and triplication copy number mutations, we did not identify any further gross rearrangements in any of the four genes in the studied cohort (see below).

Since we aimed to be conservative in our estimate of the major genetic cause of ICP, we excluded synonymous, intronic and 5'- or 3'-untranslated region variants in the four genes from consideration except where there was persuasive evidence of a functional consequence. All remaining variants (available in an Excel format in Supplementary Table S1) will be discussed in the context of their associated genes, followed by a consideration of potential gene-gene interactions in accordance with the principles set out in Figure 1. In particular, the 22 patients found to exhibit gene-gene interactions are described in Figure 2.

Rare causative *PRSS1* mutations account for 9.1% of the ICP study group

Heterozygous variants in the *PRSS1* gene were identified in 25 of the 253 ICP patients (Supplementary Table S1). Of these, p. P36R was found in a single male subject; this variant had been previously reported in a French female ICP patient but not in 400 French healthy controls [29]. However, a recent functional analysis has suggested that this variant may not be of any pathological relevance [30]. p. E79K was also found only once; this variant has been previously reported in several studies [29,31–34] whilst functional analysis has suggested a possible pathogenic mechanism involving trans-trypsinogen activation [32]. However, p. E79K was found to be present in both French and Brazilian controls, with allele frequencies of 0.25% [29] and 0.33% [31], respectively. From a conservative standpoint, and given the general rule that the representation of gain-of-function mutations in a given gene is likely to be very limited, these two missense mutations were classified as neutral alleles.

By contrast, neither the *PRSS1* gene duplication ($\times 4$) and triplication ($\times 9$) copy number mutations, nor the p. N29I ($\times 4$),

p.R122H ($\times 3$), p.R122C ($\times 1$), p.R166C ($\times 1$), and p. A16V ($\times 1$) missense mutations have ever been described in unrelated healthy controls. Moreover, each lesion was either presumed (in the case of copy number mutations) or experimentally shown (in the case of missense mutations) to have a plausible pathogenic mechanism leading to chronic pancreatitis (for references, see 35). Taken together with the key role of *PRSS1* in the aetiology of chronic pancreatitis [8], all these *PRSS1* mutations could be regarded as causing the disease in their respective carriers ($N = 23$), accounting for 9.1% of the 253 ICP patients screened (Table S1).

SPINK1 variants either caused or contributed to ICP in 6.7% and 9.1% of cases respectively

Based on the observation that some of the most severe *SPINK1* alleles (e.g. micro-deletions and splice site mutations) were reported in families with hereditary pancreatitis, we concluded that haploinsufficiency of the *SPINK1* gene is sufficient to cause the disease [8]. In line with this postulate, partially functional *SPINK1* alleles can be assumed to predispose to the disease in a dosage-dependent manner. Such a dosage-dependent influence may however often have been masked by the variable penetrance and expressivity of the condition.

Variants in the *SPINK1* gene were found in 42 of the 253 ICP subjects screened (Table S1). Of these, p. P55S, which was found in three cases, is an unambiguous neutral polymorphism; it was found both in cases and controls with comparable frequencies [13,19,36] and exhibited no functional effect when characterized *in vitro* [37,38].

p. N34S, in the simple heterozygous state (e.g. patient 4, Figure 2), was present in 9.1% ($N = 23$) of the 253 studied ICP cases [p. N34S may not be of functional significance *per se* and may simply represent a marker of its associated haplotype [39,40]]. Since heterozygous p. N34S is present in $\sim 0.75\%$ of the French population [41], the p. N34S-associated haplotype would appear to increase the risk of ICP by ~ 12 -fold. This is consistent with the two largest and most relevant studies to date, which reported a 10–15 fold increased risk for chronic pancreatitis [19,42].

Homozygous p. N34S (e.g. patient 18, Figure 2) was present in 5.5% ($N = 14$) of the 253 ICP cases. By way of comparison, combined data from eight studies performed in Europe and the United States indicate that $\sim 3.6\%$ of chronic pancreatitis patients are homozygous for p. N34S [18]; the corresponding proportion from the recent Rosendahl study was 2.6% [19]. In addition, in the Rosendahl study, the frequency of homozygous p. N34S in the <20 years group was higher than in the >20 years group [3.1% (13/421) vs. 1.7% (4/239)], although this difference was not statistically significant owing to the small sample size.

We may assume that homozygosity for p. N34S serves to double the functional effect of a single heterozygous p. N34S allele. However, this quantitative addition may lead to a qualitative change in terms of phenotype expression were it to reduce the *SPINK1* expression below a threshold level that is sufficient to cause the disease. Another important point is that, to date, no p. N34S homozygote has ever been reported from a




Figure 1. Principles of variant classification in terms of their pathogenic relevance. See Results and Discussion for details.

doi: 10.1371/journal.pone.0073522.g001

Patient	<i>PRSS1</i>	<i>SPINK1</i>	<i>CTRC</i>	<i>CFTR</i>
4	-/-	N34S/-	-/-	F508del/L967S
9	-/-	N34S/-	-/-	L967S/-
18	-/-	N34S/N34S	V235I/-	-/-
31	-/-	N34S/-	K247_R254del/-	R1162L/-
32	-/-	N34S/-	-/-	G542X/L188P
36	-/-	N34S/-	-/-	H1054D/G1069R
40	-/-	N34S/-	-/-	11TG-5T/-
48	-/-	N34S/-	R254W/-	-/-
49	-/-	N34S/-	-/-	F508del/E1124del
57	-/-	N34S/N34S	-/-	12TG-5T/-
68	-/-	-/-	C155Y/-	L997F/-
73	-/-	N34S/N34S	-/-	F508del/-
76	-/-	N34S/-	-/-	R117G/11TG-5T
77	-/-	N34S/-	-/-	F508del/S1235R
89	N29I/-	-/-	-/-	F508del/-
98	-/-	-/-	G217S/R254W	G85E/L568F
102	R122H/-	-/-	-/-	11TG-5T/-
110	N29I/-	-/-	-/-	G576A-R668C/-
115	R116C/-	N34S/-	-/-	-/-
125	-/-	[N34S;R65Q]/[N34S;R65Q]	-/-	G622D/11TG-5T
126	-/-	N34S/-	-/-	F508del/L206W
131	-/-	-/-	W55X/-	12TG-5T/-

Figure 2. 22 ICP patients displaying evidence of a digenic inheritance pattern. In *PRSS1*, *SPINK1* and *CTRC*, the variants or genotypes classified variously as causative, contributory or neutral are given in red, blue and black, respectively. In *CFTR*, the alleles classified individually as severe, mild or associated with *CFTR*-related disorders, and neutral are in green, violet and black, respectively. See text for details regarding the definition of causative, contributory and neutral *CFTR* genotypes and gene-gene interactions.

doi: 10.1371/journal.pone.0073522.g002

control population [18,19,42]. Given the already >10-fold increased risk conferred by the heterozygous p. N34S variant, we believe that it is not unreasonable to classify homozygous p. N34S as disease-causing. By way of reference, according to the rare allele model of complex disease, rare variants (allele frequency typically <1% in the normal population) that confer an elevated risk two-fold or more above background, are generally held to be the main cause of the disease in question [43].

Three known rare *SPINK1* mutations, p. M1 [13]? , IVS2+1G > A [21] and IVS3+2T>C [13], each of which was found once in the current study, were deemed to be disease causing by virtue of their predicted functional consequences. These three mutations (and other presumed or experimentally demonstrated loss-of-function mutations) in the *SPINK1* gene were almost invariably found in patients rather than controls [8,19].

The aforementioned p. M1? variant was identified in *trans* with p. N34S (i.e. a compound heterozygote) in patient 45

(Table S1). In addition, one of the 14 p. N34S homozygotes was in fact doubly homozygous for p. N34S and p. R65Q (patient 125, Figure 2). p. R65Q is itself of pathogenic relevance, reducing *SPINK1* protein expression to 40% of normal [37,38]. Since heterozygous p. M1? and homozygous p. N34S have both been regarded as disease-causing, these combinations do not alter the carrier frequency with respect to disease-causing *SPINK1* genotypes.

In summary, *SPINK1* variants caused the disease in 6.7% (N = 17) of the studied cases and could have contributed to disease development in an additional 9.1% (N =23) of cases. Taken together, pathological *SPINK1* variants were found in 15.8% of ICP cases (Table S1).

Rare *CTRC* genotypes contributed to the development of ICP in 4.3% of cases

CTRC has conventionally been regarded as being the least important gene in terms of a genetic predisposition to chronic

pancreatitis, as compared with *PRSS1* and *SPINK1* [8]. This view received further support from two recent developments. First, some of the *CTRC* variants characterized by a complete or virtually complete functional loss of the affected alleles, exemplified by p.K247_R254del and p. G217S, have been reported in unrelated healthy controls [44]. Second, whereas a heterozygous *CTRC* whole gene deletion was found in *trans* with other genetic predisposing alleles in two subjects with familial chronic pancreatitis, a different homozygous *CTRC* whole gene deletion was identified in a patient with asymptomatic ICP [45]. Employing the functionally null *CTRC* allele, p.K247_R254del, which increases the risk of ICP 6.4-fold [44], as a reference (N.B. the heterozygous *SPINK1* p. N34S allele confers a >10-fold increased risk), any loss-of-function variants in the *CTRC* gene may at most be interpreted as disease-predisposing.

Variants in the *CTRC* gene were found in only 14 subjects in this study (Table S1). Of these, three missense mutations, p.K172E, p.R162H and p.M200V, each found only once, were classified as neutral variants on the basis of functional analysis [44]. All the other variants were either clearly pathogenic (p. W55X) or experimentally demonstrated (p.R254W, p.V235I, p.K247_R254del, p. A37T, p. C155Y, p. G217S, and p.G217R) loss-of-function variants. For reasons of simplicity and from a conservative viewpoint, all these variants, irrespective of (i) their occurrence in the heterozygous (e.g. patient 18) or compound heterozygous (e.g. patient 98, Figure 2) state and (ii) being classified as high risk or moderate-to-low risk variants by Beer and colleagues [44], were here invariably classified as being disease contributory. Consequently, *CTRC* susceptibility variants were found to be present in 4.3% (N = 11) of the patient group (Table S1).

***CFTR* genotypes contributed to, or caused, ICP in ~24% and 4.0% of cases, respectively**

A diverse range of *CFTR* variants/genotypes were found in a total of 99 ICP cases (Table S1). As indicated in Figure 1, these variants were first divided into three categories on an individual basis. For example, F508del, L967S and R1162L (Figure 2) fell into the A (cystic fibrosis-causing severe alleles), B (cystic fibrosis mild alleles and those associated with *CFTR*-related disorders [7]) and C (the remaining *CFTR* alleles) categories, respectively. In general, we treated those alleles of unknown significance conservatively by placing them into the C category. Of particular note, p. R75Q was placed in category C on the basis that it was not overrepresented in our patient cohort [4.7% (12/253)] as compared with a sample of 514 French controls [4.9% (25/514)]. This finding concurs with that of the recent Rosendahl study [19] but differed from that of Schneider et al. [46]. In the latter study, p. R75Q was reported to be overrepresented in patients as compared to controls (16% vs. 5.3%). Contrary to the findings of the Schneider study [46], we did not find any preferential co-occurrence of *CFTR* p. R75Q with *SPINK1* p. N34S; only two of our seven heterozygous *CFTR* p. R75Q patients also carried a heterozygous *SPINK1* p. N34S (patients 19 and 130, Table S1).

Based on our current knowledge of the *CFTR* genotype/phenotype relationship, *CFTR* genotypes in each of the 99 subjects (i.e. both the two alleles were taken into consideration) were classified as causative, contributory or neutral in accordance with the combinations of the A, B and C category alleles (Figure 1). For example, the compound heterozygote in patient 4 was regarded as being causative because it comprised a category A allele plus a category B allele; the genotypes in patients 73, 9 and 36 were regarded merely as contributory because they comprised a simple heterozygous category A allele, a simple heterozygous category B allele and two category B alleles, respectively; by contrast, the genotype in patient 31 was held to be neutral because it comprised a simple category C allele (Figure 2). In accordance with this classificatory scheme, 4.0% (N = 10) of the patients carried a causative *CFTR* genotype whilst 23.7% (N = 60) carried a contributory genotype (Table S1).

Gene-gene interactions were found in ~9% of ICP patients

122 ICP cases were found to carry at least one contributory or causative genotype as assigned in this study (indicated by x or xx in column F, Table S1), accounting for 48.2% of the 253 studied patients. Of these 122 cases, 100 carried a single pathological genotype (indicated by 1, 2, 3 or 4 in column G, Table S1), 22 carried two pathological genotypes in two different genes (termed digenic genotypes; indicated by 12, 14, 23, 24 or 34 in column G, Table S1; see also Figure 2). All of the 22 latter cases, accounting for 8.7% of the 253 ICP patients, comprised at the most only one disease-causing genotype. Here it is pertinent to mention that in the Rosendahl study [19], *trans*-heterozygotes were found in 43/660 (6.5%) patients and 3/1667 (0.2%) controls ($P < 0.0001$), OR 38.7; 95% CI 12 to 125.1).

Of the aforementioned 22 cases, 18 involved a pathological *CFTR* genotype (Figure 2), presumably due to the relatively high frequency of pathological *CFTR* genotypes in the patients. Of the 18 cases involving a pathological *CFTR* genotype, 12 harboured a pathological *SPINK1* genotype, 3 a pathological *PRSS1* genotype, whilst the remaining 3 also harboured a pathological *CTRC* genotype (Figure 2). It should be noted that in the 12 *CFTR/SPINK1* digenic pathological genotypes, the *SPINK1* partner was invariably the p. N34S variant (heterozygous × 10; homozygous × 3) (Figure 2).

Of the 22 digenic pathological genotypes, 12 comprised a disease-causing genotype and a contributory genotype (patients 4, 18, 32, 49, 57, 73, 89, 102, 110, 115, 125 and 126; Figure 2). The remaining 10 cases comprised two contributory genotypes (patients 9, 31, 36, 40, 48, 68, 76, 77, 98 and 131; Figure 2). These 10 cases were further assigned as causative due to the presumed additive or potentially synergistic effects of their component contributory genotypes involving two genes. This approach increased the number of causative genotypes to 60, representing 23.7% of the 253 ICP patients screened. Finally, contributory genotypes were found in an additional 24.5% (N = 62) of cases. Taken together, up to 48.2% of the studied ICP patients were found to display evidence of a genetic basis for their pancreatitis (Figure 3).




Figure 3. An overview of the major genetic cause of ICP resulting from the analysis of the four major pancreatitis genes in 253 young French ICP patients. Numbers in bold indicate the contributory and causative variants/genotypes assigned in the context of the *PRSS1*, *SPINK1*, *CTRC* and *CFTR* genes, individually. Numbers in shaded circles indicate evidence of a digenic inheritance pattern comprising a causative genotype in a gene modulated by a contributory genotype in another gene. Numbers in non-filled circles indicate two contributory genotypes in two distinct genes (refer to Figure 2); these digenic genotypes were further assigned as causative by taking into consideration the presumed additive or potentially synergistic effects of their component genotypes. The final counts of contributory, causative and contributory plus causative genotypes are also provided.

doi: 10.1371/journal.pone.0073522.g003

Conclusions and perspective

We systematically screened a large and fairly homogeneous sample of ICP patients for both conventional types of mutation and gross genomic rearrangements involving the four most extensively studied chronic pancreatitis-causing or -predisposing genes. Although the extensive locus and allelic heterogeneity of the disease presents a major challenge, we have devised a classificatory scheme that should serve as an invaluable aid in dissecting the complex genetic determinants of ICP. This notwithstanding, we would like to make three points. First, the proposed variant classification scheme should not be regarded as definitive and is certainly likely to be subject to modification and improvement over time in the light of new genetic, epidemiological and functional data as they emerge. Second, the particular proportions we obtained in the 253

young French patients may not be extrapolable to ICP patients from other populations and different age groups. For example, trypsinogen duplication and triplication copy number mutations were detected in 5.1% (N = 13) of the 253 cases; to date, they have not been reported by other groups. Whether this is due to the absence of such events in other populations or simply due to the fact that they have not been sought in a methodical fashion is unclear. Third, and relevant to the 'conservative' nature of the study, it is worth pointing out that the intronic regions of the four major genes were not screened for mutations. Despite these limitations, we have demonstrated that a prerequisite for understanding the genotype-phenotype relationship in a complex disease such as ICP is not a simple variant number count but rather an overall assessment, made

on an individualized basis, of the net effect of an oligogenic variant profile on the eventual risk of disease.

Supporting Information

Table S1. Variants/genotypes reported in the current study.

In columns B, C and D, the variants or genotypes classified variously as causative, contributory or neutral are given in red, blue and black, respectively. In column E, the CFTR alleles classified individually as severe, mild or associated with CFTR-related disorders, and neutral are in green, violet and black, respectively. In column F, x and xx indicate contributory and

causative genotypes, respectively, with gene-gene interactions being taken into consideration. In column G, 1, 2, 3 and 4 refer to pathological PRSS1, SPINK1, CTSC and CFTR genotypes, respectively. See text for details.

(XLS)

Author Contributions

Conceived and designed the experiments: EM JMC CF. Performed the experiments: EM MPA. Analyzed the data: EM JMC MPA DNC CF. Contributed reagents/materials/analysis tools: CF. Wrote the manuscript: JMC DNC CF.

References

- Spanier BW, Dijkgraaf MG, Bruno MJ (2008) Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. *Best Pract Res Clin Gastroenterol* 22: 45-63. doi:10.1016/j.bpg.2007.10.007. PubMed: 18206812.
- Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM et al. (1998) Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. *N Engl J Med* 339: 653-658. doi:10.1056/NEJM199809033391002. PubMed: 9725922.
- Sharer N, Schwarz M, Malone G, Howarth A, Painter J et al. (1998) Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. *N Engl J Med* 339: 645-652. doi:10.1056/NEJM199809033391001. PubMed: 9725921.
- Poulsen JH, Fischer H, Illek B, Machen TE (1994) Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Natl Acad Sci U S A* 91: 5340-5344. doi:10.1073/pnas.91.12.5340. PubMed: 7515498.
- Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH et al. (2004) Gating of CFTR by the STAS domain of SLC26 transporters. *Nat Cell Biol* 6: 343-350. doi:10.1038/ncb1115. PubMed: 15048129.
- Park HW, Nam JH, Kim JY, Namkung W, Yoon JS et al. (2010) Dynamic regulation of CFTR bicarbonate permeability by $[Cl^-]$ and its role in pancreatic bicarbonate secretion. *Gastroenterology* 139: 620-631. doi:10.1053/j.gastro.2010.04.004. PubMed: 20398666.
- Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J et al. (2011) Recommendations for the classification of diseases as CFTR-related disorders. *J Cyst Fibros* 10 Suppl 2: S86-102. doi:10.1016/j.jcf.2010.10.004. PubMed: 21658649.
- Chen JM, Férec C (2009) Chronic pancreatitis: genetics and pathogenesis. *Annu Rev Genomics Hum Genet* 10: 63-87. doi:10.1146/annurev-genom-082908-150009. PubMed: 19453252.
- Creighton J, Lyall R, Wilson DI, Curtis A, Charnley R (1999) Mutations of the cationic trypsinogen gene in patients with chronic pancreatitis. *Lancet* 354: 42-43. doi:10.1016/S0140-6736(99)01814-0. PubMed: 10406366.
- Witt H, Luck W, Becker M (1999) A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. *Gastroenterology* 117: 7-10. doi:10.1016/S0016-5085(99)70543-3. PubMed: 10381903.
- Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ et al. (1996) Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nat Genet* 14: 141-145. doi:10.1038/ng1096-141. PubMed: 8841182.
- Masson E, Le Maréchal C, Chandak GR, Lamoril J, Bezieau S et al. (2008) Trypsinogen copy number mutations in patients with idiopathic chronic pancreatitis. *Clin Gastroenterol Hepatol* 6: 82-88. doi:10.1016/j.cgh.2007.10.004. PubMed: 18063422.
- Witt H, Luck W, Hennies HC, Classen M, Kage A et al. (2000) Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. *Nat Genet* 25: 213-216. doi:10.1038/76088. PubMed: 10835640.
- Szmola R, Sahin-Tóth M (2007) Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y. *Proc Natl Acad Sci U S A* 104: 11227-11232. doi:10.1073/pnas.0703714104. PubMed: 17592142.
- Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvári B et al. (2008) Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. *Nat Genet* 40: 78-82. doi:10.1038/ng.2007.44. PubMed: 18059268.
- Masson E, Chen JM, Scotet V, Le Maréchal C, Férec C (2008) Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. *Hum Genet* 123: 83-91. doi:10.1007/s00439-007-0459-3. PubMed: 18172691.
- Whitcomb DC (2010) Genetic aspects of pancreatitis. *Annu Rev Med* 61: 413-424. doi:10.1146/annurev.med.041608.121416. PubMed: 20059346.
- Witt H, Apte MV, Keim V, Wilson JS (2007) Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. *Gastroenterology* 132: 1557-1573. doi:10.1053/j.gastro.2007.03.001. PubMed: 17466744.
- Rosendahl J, Landt O, Bernadova J, Kovacs P, Teich N et al. (2013) CFTR, SPINK1, CTSC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? *Gut* 62: 582-592. doi:10.1136/gutjnl-2011-300645. PubMed: 22427236.
- Le Maréchal C, Bretagne JF, Raguénès O, Quéré I, Chen JM et al. (2001) Identification of a novel pancreatitis-associated missense mutation, R116C, in the human cationic trypsinogen gene (PRSS1). *Mol Genet Metab* 74: 342-344. doi:10.1006/mgme.2001.3246. PubMed: 11708864.
- Le Maréchal C, Chen JM, Le Gall C, Plessis G, Chipponi J et al. (2004) Two novel severe mutations in the pancreatic secretory trypsin inhibitor gene (SPINK1) cause familial and/or hereditary pancreatitis. *Hum Mutat* 23: 205. doi:10.1002/humu.9213. PubMed: 14722925.
- Le Maréchal C, Audrezet MP, Quéré I, Raguénès O, Langonné S et al. (2001) Complete and rapid cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling. *Hum Genet* 108: 290-298. doi:10.1007/s004390100490. PubMed: 11379874.
- Audrezet MP, Dabricot A, Le Maréchal C, Férec C (2008) Validation of high-resolution DNA melting analysis for mutation scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. *J Mol Diagn* 10: 424-434. doi:10.2353/jmoldx.2008.080056. PubMed: 18687795.
- Friedman KJ, Heim RA, Knowles MR, Silverman LM (1997) Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. *Hum Mutat* 10: 108-115. doi:10.1002/(SICI)1098-1004(1997)10:2. PubMed: 9259194.
- Mantovani V, Garagnani P, Selva P, Rossi C, Ferrari S et al. (2007) Simple method for haplotyping the poly(TG) repeat in individuals carrying the IVS8 5T allele in the CFTR gene. *Clin Chem* 53: 531-533. doi:10.1373/clinchem.2006.074807. PubMed: 17234733.
- Le Maréchal C, Masson E, Chen JM, Morel F, Ruzsniwski P et al. (2006) Hereditary pancreatitis caused by triplication of the trypsinogen locus. *Nat Genet* 38: 1372-1374. doi:10.1038/ng1904. PubMed: 17072318.
- Masson E, Le Maréchal C, Levy P, Chuzhanova N, Ruzsniwski P et al. (2007) Co-inheritance of a novel deletion of the entire SPINK1 gene with a CFTR missense mutation (L997F) in a family with chronic pancreatitis. *Mol Genet Metab* 92: 168-175. doi:10.1016/j.ymgme.2007.06.006. PubMed: 17681820.

28. Audrézet MP, Chen JM, Raguénès O, Chuzhanova N, Giteau K et al. (2004) Genomic rearrangements in the *CFTR* gene: extensive allelic heterogeneity and diverse mutational mechanisms. *Hum Mutat* 23: 343-357. doi:10.1002/humu.20009. PubMed: 15024729.
29. Chen JM, Piepoli Bis A, Le Bodic L, Ruzsniwski P, Robaszkievicz M et al. (2001) Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis. *Clin Genet* 59: 189-193. doi:10.1034/j.1399-0004.2001.590308.x. PubMed: 11260229.
30. Schnúr A, Beer S, Witt H, Hegyi P, Sahin-Tóth M (2013) Functional effects of 13 rare *PRSS1* variants presumed to cause chronic pancreatitis. *Gut*: ([MedlinePgn:]) doi:10.1136/gutjnl-2012-304331. PubMed: 23455445. PubMed: 23455445
31. Bernardino AL, Guarita DR, Mott CB, Pedrosa MR, Machado MC et al. (2003) *CFTR*, *PRSS1* and *SPINK1* mutations in the development of pancreatitis in Brazilian patients. *Jop* 4: 169-177. PubMed: 14526128.
32. Teich N, Le Maréchal C, Kukor Z, Caca K, Witzigmann H et al. (2004) Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (*PRSS1*) causes increased transactivation of anionic trypsinogen (*PRSS2*). *Hum Mutat* 23: 22-31. doi:10.1002/humu.10285. PubMed: 14695529.
33. Keiles S, Kammesheidt A (2006) Identification of *CFTR*, *PRSS1*, and *SPINK1* mutations in 381 patients with pancreatitis. *Pancreas* 33: 221-227. doi:10.1097/01.mpa.0000232014.94974.75. PubMed: 17003641.
34. Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Le Maréchal C et al. (2009) The natural history of hereditary pancreatitis: a national series. *Gut* 58: 97-103. doi:10.1136/gut.2008.149179. PubMed: 18755888.
35. Chen JM, Férec C (2012) Genetics and pathogenesis of chronic pancreatitis: the 2012 update. *Clin Res Hepatol Gastroenterol* 36: 334-340. doi:10.1016/j.clinre.2012.05.003. PubMed: 22749696.
36. Chen JM, Mercier B, Audrezet MP, Férec C (2000) Mutational analysis of the human pancreatic secretory trypsin inhibitor (*PSTI*) gene in hereditary and sporadic chronic pancreatitis. *J Med Genet* 37: 67-69. doi:10.1136/jmg.37.1.67. PubMed: 10691414.
37. Boulling A, Le Maréchal C, Trouvé P, Raguénès O, Chen JM et al. (2007) Functional analysis of pancreatitis-associated missense mutations in the pancreatic secretory trypsin inhibitor (*SPINK1*) gene. *Eur J Hum Genet* 15: 936-942. doi:10.1038/sj.ejhg.5201873. PubMed: 17568390.
38. Király O, Wartmann T, Sahin-Tóth M (2007) Missense mutations in pancreatic secretory trypsin inhibitor (*SPINK1*) cause intracellular retention and degradation. *Gut* 56: 1433-1438. doi:10.1136/gut.2006.115725. PubMed: 17525091.
39. Kereszturi E, Király O, Sahin-Tóth M (2009) Minigene analysis of intronic variants in common *SPINK1* haplotypes associated with chronic pancreatitis. *Gut* 58: 545-549. doi:10.1136/gut.2008.164947. PubMed: 18978175.
40. Boulling A, Chen JM, Férec C (2012) Is the *SPINK1* p.Asn34Ser missense mutation *per se* the true culprit within its associated haplotype? *WebmedCentral Genet* 3: WMC003084
41. Chen JM, Mercier B, Audrezet MP, Raguénès O, Quéré I et al. (2001) Mutations of the pancreatic secretory trypsin inhibitor (*PSTI*) gene in idiopathic chronic pancreatitis. *Gastroenterology* 120: 1061-1064. doi:10.1053/gast.2001.23094. PubMed: 11265669.
42. Aoun E, Chang CC, Greer JB, Papachristou GI, Barmada MM et al. (2008) Pathways to injury in chronic pancreatitis: decoding the role of the high-risk *SPINK1* N34S haplotype using meta-analysis. *PLOS ONE* 3: e2003. doi:10.1371/journal.pone.0002003. PubMed: 18414673.
43. Gibson G (2011) Rare and common variants: twenty arguments. *Nat Rev Genet* 13: 135-145. PubMed: 22251874.
44. Beer S, Zhou J, Szabó A, Keiles S, Chandak GR et al. (2012) Comprehensive functional analysis of chymotrypsin C (*CTRC*) variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk. *Gut*: ([MedlinePgn:]) doi:10.1136/gutjnl-2012-303090. PubMed: 22942235. PubMed: 22942235
45. Masson E, Hammel P, Garceau C, Bénech C, Quéméner-Redon S et al. (2013) Characterization of two deletions of the *CTRC* locus. *Mol Genet Metab* 109: 296-300. doi:10.1016/j.ymgme.2013.04.022. PubMed: 23721890.
46. Schneider A, Larusch J, Sun X, Aloe A, Lamb J et al. (2011) Combined bicarbonate conductance-impairing variants in *CFTR* and *SPINK1* variants are associated with chronic pancreatitis in patients without cystic fibrosis. *Gastroenterology* 140: 162-171. doi:10.1053/j.gastro.2010.10.045. PubMed: 20977904.